Mechanism: Clonal Hematopoietic Stem Cells (CHSCs) with DNMT3A mutations dominate the bone marrow niche in aged states, suppressing healthy hematopoiesis and driving systemic inflammation. Readout: Readout: Therapeutic inhibition of DNMT3A reduces CHSC dominance, restores healthy blood cell production, and decreases systemic inflammation, leading to an improved systemic aging score.